Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Extrinsic and Intrinsic Pathways of Hemostasis

Extrinsic and Intrinsic Pathways of Hemostasis

Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...

Clot Retraction and Fibrinolysis

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.

Venous Thrombosis I: Introduction

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...

Coagulation

Coagulation

The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...

Formation of the Platelet Plug

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Is leukocyte tissue factor the key to venous thrombosis in antiphospholipid syndrome?

Journal of thrombosis and haemostasis : JTH·2016

Same author

Antiphospholipid antibody-mediated effects in an arterial model of thrombosis are dependent on Toll-like receptor 4.

Lupus·2015

Same author

Risky business: the interpretation, use, and abuse of antiphospholipid antibody tests in clinical practice.

Lupus·2010

Same author

Serum complement activation on heterologous platelets is associated with arterial thrombosis in patients with systemic lupus erythematosus and antiphospholipid antibodies.

Lupus·2009

Same author

[Accumulation of heat-shock proteins 70 in insect fat bodies as evidence of stress in Microsporidia-infected insects].

Tsitologiia·2004

Same author

Differences by race, sex and age in the clinical and immunologic features of recently diagnosed systemic lupus erythematosus patients in the southeastern United States.

Lupus·2002

Search research articles

Related Experiment Video

Updated: Jun 29, 2026

Extracellular Vesicle Tissue Factor Activity Assay

Extracellular Vesicle Tissue Factor Activity Assay

Published on: December 29, 2023

Tissue factor in the antiphospholipid syndrome.

A V Kinev¹, R A S Roubey

¹Department of Medicine and Thurston Arthritis Research Center, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599-7280, USA.

|October 2, 2008

Summary

Antiphospholipid antibodies increase thrombosis risk by upregulating tissue factor (TF). Targeting TF may offer new treatments for antiphospholipid syndrome, a condition causing blood clots and pregnancy loss.

More Related Videos

Flow Cytometry Analysis of Tissue Factor Expression in Human Platelets

Flow Cytometry Analysis of Tissue Factor Expression in Human Platelets

Published on: November 22, 2024

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

Related Experiment Videos

Last Updated: Jun 29, 2026

Extracellular Vesicle Tissue Factor Activity Assay

Extracellular Vesicle Tissue Factor Activity Assay

Published on: December 29, 2023

Flow Cytometry Analysis of Tissue Factor Expression in Human Platelets

Flow Cytometry Analysis of Tissue Factor Expression in Human Platelets

Published on: November 22, 2024

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

Area of Science:

Hematology
Immunology
Vascular Biology

Background:

Antiphospholipid (aPL) antibodies are acquired risk factors for thrombosis and pregnancy loss.
These antibodies are associated with a prothrombotic state.
Tissue factor (TF) is a key initiator of blood coagulation and thrombosis.

Purpose of the Study:

To review the physiology of tissue factor (TF).
To discuss the molecular regulation of TF expression.
To examine the effects of aPL antibodies on intravascular TF regulation and expression.

Main Methods:

Literature review of TF physiology and regulation.
Analysis of studies on aPL antibody effects on TF.
Synthesis of information on TF's role in antiphospholipid syndrome.

Main Results:

aPL antibodies contribute to thrombophilia by upregulating TF on blood cells and endothelium.
TF is the physiological trigger for coagulation and thrombosis in hypercoagulable states.
Understanding aPL-induced TF expression is crucial for managing antiphospholipid syndrome.

Conclusions:

TF upregulation is a major mechanism for aPL antibody-induced thrombophilia.
Inhibiting TF presents a potential therapeutic strategy for antiphospholipid syndrome.
Further research into aPL-induced TF pathways could yield novel treatments.